Stock VTRS VIATRIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Viatris Inc.

Equities

VTRS

US92556V1061

Real-time Estimate Cboe BZX
Other stock markets
 10:37:00 2024-05-08 am EDT 		5-day change 1st Jan Change
11.9 USD +1.49% Intraday chart for Viatris Inc. +2.06% +9.60%
Apr. 18 Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says MT
Apr. 18 UK Regulator to Consider Undertakings for Theramex-Viatris Deal MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Viatris to Participate in the BofA Securities 2024 Health Care Conference
PR
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
PR
Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says
MT
UK Regulator to Consider Undertakings for Theramex-Viatris Deal
MT
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
PR
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada
MT
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
AQ
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
PR
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer
CI
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
AQ
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada
CI
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order
MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc
CI
UK's Theramex sees no impact to HRT products supply after CMA probe
RE
Pharma deal could reduce choice and lead to higher prices for HRT treatments
AQ
UK Regulator Finds Competition Concerns in Theramex-Viatris Merger Deal
MT
UK watchdog says Theramex-Viatris deal raises competition concerns
RE
Viatris Announces the Launch of RYZUMVl 0.75% in the United States
AQ
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review
MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VTRS Stock
  4. News Viatris Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW